Compare Bank of New York Mellon Corp (BNY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Inovio Pharmaceuticals Inc — how do they compare? Bank of New York Mellon Corp trades at $162.84 (market cap $108.78B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Bank of New York Mellon Corp is far larger — about 1384.9× Inovio Pharmaceuticals Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BNY | INO | |
|---|---|---|
Market Cap | $108.78B | $78.55M |
Sector | Financials | Health |
52-Week High | $162.35 | $2.87 |
52-Week Low | $101.00 | $0.66 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.92, up 2.18% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.46 beating estimates and consistent revenue growth from $19.76B in 2025 to $21.0B projected for 2026. Analyst sentiment remains positive with 10 buy ratings and a $170.36 consensus price target, supported by recent digital transfer agency expansion and blockchain infrastructure collaborations.
Outlook remains favorable with earnings momentum and digital innovation driving growth, though elevated RSI levels suggest near-term consolidation risk. The stock offers 4.6% upside to consensus target with strong institutional support, balanced by competitive pressures in custody banking and interest rate sensitivity as key monitoring points.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
